SAB Biotherapeutics, Inc.
SABSW
Last
$0.01
Day
+4.5%
1y
-82.7%
5y
-99.4%
52w
-95.5%
SPY YTD
+13.3%
Sec
—
Earnings
—
EMA 21
0.01
EMA 50
0.02
EMA 200
0.02
20d high
-76.2%
5y high
-99.7%
5y range
0th
Positions held
Your positionsSABSW isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-30
Hold
avoid
Signal
Strong Sell
Target
$0.02
Stop
$0.00
Stop distance
100.0%
Target vs last
+117.4%
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | 0.03 | Forward P/E | — |
| PEG | — | Price / book | 0.00 | Beta | 0.58 | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -11.3% | ROA | -33.5% | Debt / equity | 0.02 |
| Current ratio | 9.22 | Free cash flow | -$28.84M | Analyst recommendation | none | Mean target | — |
| 52w high | $0.01 | 52w low | $0.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$22.5M | -$18.9M | -$16.9M | $45.4M | -$10.1M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.4M | -$20.0M | -$15.8M | -$12.7M | -$9.7M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | $13.3M | -$34.1M | -$42.2M | -$18.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$49.0M | -$42.9M | -$38.1M | -$28.9M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
Price (daily)
Full chart · RSI · MACD · patternsSABSW · daily-41.1% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin